Sanofi's lixisenatide aces Phase III

Sanofi-Aventis says a late-stage trial of its experimental diabetes drug lixisenatide help cut blood sugar, body weight and glucose. The  drug, which belongs to the GLP-1 class, is just one program in the French drug developer's effort to expand its offerings in the growing diabetes field. If approved, lixisenatide would compete with with Victoza and Byetta, according to Reuters. Report

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.